Logo

American Heart Association

  2
  0


Final ID: 4136452

Acute Cardiac Function Change After Catheter Ablation of Ventricular Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy

Abstract Body (Do not enter title and authors here): Introduction Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder characterized by fibrofatty replacement of myocardial tissue, creating areas of electrical heterogeneity and increasing the risk of ventricular arrhythmias (VAs) and sudden cardiac death (SCD). Catheter ablation is commonly performed in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) for management of ventricular arrhythmias (VAs). Whether catheter ablation affects cardiac function post-procedurally is uncertain.
Research Question: Does catheter ablation for ARVC result in acute change in cardiac function?
Goals/Aims To assess the impact of catheter ablation for VAs on cardiac function in the acute post-procedure setting.
Methods This retrospective study included patients with ARVC who underwent catheter ablation for VAs at Mayo Clinic. Cardiac function was assessed on pre- and post-procedure transthoracic echocardiograms (TTEs). Post-procedure TTEs were obtained within 4 weeks after the ablation procedure. Right ventricular (RV) enlargement and systolic dysfunction were evaluated as continuous variables (0=none, 1=mild, 2=mild-moderate, 3=moderate, 4=moderate-severe, 5=severe).
Results The study included 32 patients who underwent a total of 44 ablations. Mean age at the time of ablation was 49±16 years, and 24 (75%) were male. After a mean follow-up duration of 2.6±5.5 days, there was a significant worsening in mean RV dysfunction (1.6±1.5 to 2.0±1.4, P= 0.001). There were no significant changes in mean left ventricular ejection fraction (LVEF), left ventricular (LV) dimensions, and RV size. 6 (14%) patients had a >5% decline in LVEF, and 14 (32%) patients had worsening RV function. Transient inotropic support was required in 4 (9%) patients.
Conclusion(s) This study is the first to assess the acute impact of catheter ablation for VAs on cardiac function in ARVC patients. These results underscore the importance of careful post-procedure monitoring and planning of the ablation target in these patients to avoid excessive ablation and therefore impairment in cardiac function.
  • Davis, Nathaniel  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Asirvatham, Samuel  ( MAYO FOUNDATION , Rochester , Minnesota , United States )
  • Friedman, Paul  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Killu, Ammar  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Ezzeddine, Fatima  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Sugrue, Alan  ( Mayo Clinic Rochester , Rochester , Minnesota , United States )
  • Siontis, Konstantinos  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Kapa, Suraj  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Kowlgi, Gurukripa  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Bois, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Chang, Ian C  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Author Disclosures:
    Nathaniel Davis: DO NOT have relevant financial relationships | Samuel Asirvatham: DO have relevant financial relationships ; Speaker:Abbott:Active (exists now) ; Speaker:Zoll:Active (exists now) ; Speaker:Medtronic:Active (exists now) ; Speaker:Biosense Webster:Active (exists now) ; Speaker:Biotronik:Active (exists now) | Paul Friedman: DO NOT have relevant financial relationships | Ammar Killu: DO have relevant financial relationships ; Consultant:Boston Scientific:Past (completed) ; Speaker:Abbott:Past (completed) ; Speaker:Atricure:Past (completed) ; Research Funding (PI or named investigator):Boston Scientific:Active (exists now) | Fatima Ezzeddine: DO NOT have relevant financial relationships | Alan Sugrue: No Answer | Konstantinos Siontis: No Answer | Suraj Kapa: DO NOT have relevant financial relationships | Gurukripa Kowlgi: DO NOT have relevant financial relationships | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Other (please indicate in the box next to the company name):Prolaio (equity/royalty sharing):Active (exists now) ; Research Funding (PI or named investigator):Tenaya Therapeutics:Active (exists now) | John Bois: No Answer | Ian C Chang: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Viva Voce! Veritable Voices on VT ablation

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Abstract Oral Session

More abstracts on this topic:
More abstracts from these authors:
Premature Ventricular Complexes and Nonsustained Ventricular Tachycardia in Cardiac Sarcoidosis

De Melo Jose, Siontis Konstantinos, Debertin Julia, Castrichini Matteo, Rosenbaum Andrew, Bois John, Abou-ezzeddine Omar, Kapa Suraj, Deshmukh Abhishek, Asirvatham Samuel

Upgrade to Implantable Cardioverter-Defibrillator in Patients Diagnosed with Cardiac Sarcoidosis after Permanent Pacemaker Implantation for High-Grade Atrioventricular Block

Austin Brett, Rosenbaum Andrew, Abou-ezzeddine Omar, Giudicessi John, Bois John, Bratcher Melanie, Kapa Suraj, Deshmukh Abhishek, Siontis Konstantinos

You have to be authorized to contact abstract author. Please, Login
Not Available